| NCT06528314 | A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | RECRUITING | PHASE3 | 2024-09-04 | 2029-10 | 2029-09 |
| NCT06215716 | A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis | RECRUITING | PHASE3 | 2023-12-01 | 2032-11 | 2032-11 |
| NCT06161571 | A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-10 | 2026-10 | 2026-04 |
| NCT05039450 | A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-07-30 | 2025-05 | 2023-08-25 |
| NCT04767529 | A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2021-02-16 | 2024-05-02 | 2024-05-02 |
| NCT03976401 | A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2019-05-28 | 2022-01-10 | 2021-02-10 |